Sequoia's Valeant bet hard lesson for investors - 03/29/2016

In the Margins

Sequoia's Valeant bet hard lesson for investors

March 29, 2016

By MarketWatch

Sequoia Fund investors learned a hard lesson when the fund's investment in Valeant Pharmaceuticals went bad last year. "Bad doesn’t even begin to describe the situation for Sequoia, one of the most legendary mutual funds, which has seen its reputation torched by a bad bet on a controversial stock," writes MarketWatch's Chuck Jaffe in his latest column. Robert Goldfarb, CEO of adviser Ruane, Cunniff & Goldfarb and co-manager of Sequoia, resigned his fund duties last Wednesday. Read the original column from MarketWatch.

Share Feedback Post on LinkedIn Share Article

Most Read

A Seat at the Table
Dimensional, fund board ready early '26 ETF share class debut

Dimensional Fund Advisors is preparing to launch exchange-traded fund share classes of a selection of its open-end mutual funds in the early part of 2026, and ...

A Seat at the Table
We've had A Seat at the Table — for 10 years

The very first independent chair we profiled for FBV was Leigh Wilson at Victory Funds, for our A Seat at the Table section. Victory Capital Management had recently redefined itself ...

Top of the Agenda - Governance
SEC’s ETF share class move to spur board talks, planning

The Securities and Exchange Commission's move earlier this week to greenlight Dimensional Fund Advisors' plan to offer ETF share classes of its mutual funds is likely ...

Top of the Agenda - Governance
Fewer women, minorities among new fund directors

After years of making gains in filling fund board seats, women and individuals representing minority groups lost significant ground in the most recent two-year period measured ...